How Policy is Driving Digital Health in Germany
Several recent national-level policy changes highlight an accelerating digital transformation of healthcare in Germany, building on the Digital Healthcare Act (DVG) of 2020. In January 2021, the German Federal Government passed the draft of a law that aims to now include digital nursing and elderly care applications (DiPAs) into statutory health insurance coverage complementing coverage for digital health apps (DiGAs).
NCCN 2021 Conference Highlights: Elevating Racial Equity in Cancer Care
The NCCN 2021 Annual Conference convened virtually March 18-20, drawing attendees from more than 40 countries to discuss updates to NCCN's Oncology Clinical Practice Guidelines, new and emerging therapies, best practices in oncology care, as well as keynote sessions on HPV vaccinations, racial disparities in guideline-adherent cancer care, and effects of the pandemic on cancer care.
Case Study: Optimizing Pricing Strategies for a Medical Device Product Family
A leading global device manufacturer faced a pricing strategy challenge and partnered with BHA to identify appropriate prices for a suite of three products aimed at the low-end, mid-range, and high-end of the urology market.
Is China a 300 Million or 1.4 Billion Healthcare Population Market?
Currently, there are approximately 2800+ county-level administrative regions in China, and over 70% of the total Chinese population resides in these counties, more commonly referred to as “the rural areas of China”.
A Year in Review and Looking to the Future: Four Key Healthcare Megatrends
As the new year begins, we are looking ahead to four key megatrends that we expect to shape the landscape in the year to come.
MHRA Issues Guidance on New Medical Device Regulation in UK
As a result of Brexit, the In Vitro Diagnostic Medical Device Regulations (IVDR) will not apply to Great Britain. Unlike Great Britain, the IVDR will apply in Northern Ireland from 26 May 2022.
Webinars and Digital Events
Publications
BHA Presents Study Results at the National Kidney Foundation Spring Clinical Meeting
April 2021
Dr. Datar and colleagues used conjoint analysis to estimate preferences regarding kidney disease testing from 401 PCPs via a web survey. Hypothetical patient profiles created using clinical parameters demonstrated the clinical utility of a novel kidney diagnostic used to risk-stratify patients based on the risk of kidney function decline. Read the article here.
BHA Partners with Alcon to Conduct Real-World Study Highlighting Efficiencies of Optical Biometer in Cataract Surgery
December 2020
Alcon, a global leader in eye care, collaborated with Boston Healthcare to conduct a Time-and-Motion Study to support the value communication of its novel swept-source optical coherence tomography biometer, ARGOS®. The ISPOR abstract, titled, Time Efficiencies Associated with an Innovative Optical Biometer in Cataract Surgery Planning- A Time-and-Motion Study, can be found here, and will be published in the upcoming Value in Health Journal (December 2020 Issue, Volume 23 and Issue S2).
Boston Healthcare Presents Key Findings Associated With the Use of an AI-Enabled In Vitro Diagnostic Test
27 March 2020
The Boston Healthcare team presented key findings related to the health economic value associated with the use of an AI-enabled in vitro diagnostic test to identify CKD patients with type 2 diabetes at risk for rapid kidney function decline. BHA’s Senior Vice President, Thomas Goss, made a presentation during the late-breaker session at the National Kidney Foundation Spring Clinical Meeting in March 2020.
Read the article here: https://bit.ly/2UKaJks
View the poster here: https://bit.ly/2UFIx27
Diagnostics Developers Rapidly Utilizing New Payment Codes Established by PAMA
7 November 2018
Access the article from 360Dx here.
Clinical Omics
Compliance Conundrum: Genomic Health Faces DoJ Investigation after CMS Changes Date of Service Regs
Genomic Health has disclosed that it is the subject of a U.S. Department of Justice investigation into its compliance with changes that took effect in January to Medicare’s Date of Service billing regulation. Adam Crowther, Manager, spoke with Clinical Omics about the impact on diagnostics companies. Access the Article Here.
Medical Device & Diagnostics Industry
Considering Market Access Risk as Part of Today’s M&A Process
In an exclusive published today in Medical Device and Diagnostics Industry, Vice President, Rob Wenthold discusses the key market access issues examined during the M&A process and demonstrates the importance of market access to inform M&A through case studies and business decision-making in general. Read the article here.